KZIA
Kazia Therapeutics LimitedNASDAQHealthcare$7.34+0.00%ClosedMarket Cap: $11.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.71
P/S
872.10
EV/EBITDA
2.87
DCF Value
$-0.66
FCF Yield
-52.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-92086.4%
Net Margin
-113004.6%
ROE
-116.9%
ROA
-31.4%
ROIC
-36.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $0.00 | NaN% | $-13.3M | $-12.3M | $-3.95 | — |
| Q4 2025 | $19.7K | 100.0% | $-4.8M | $-10.0M | $-6.40 | — |
| FY 2025 | $42.0K | 100.0% | $-14.2M | $-20.7M | $-18.90 | — |
| Q2 2025 | $22.3K | 100.0% | $-9.4M | $-10.5M | $-6.15 | — |
| Q4 2024 | $2.5M | 100.0% | $-19.6M | $-18.0M | $-31.20 | — |
| FY 2024 | $2.3M | 100.0% | $-28.5M | $-26.8M | $-55.00 | — |
| Q2 2024 | $5.00 | 100.0% | $-8.9M | $-8.8M | $-18.40 | — |
| Q4 2023 | $1.0K | 100.0% | $-10.5M | $-6.9M | $-15.10 | — |
| FY 2023 | $555.00 | 100.0% | $-24.1M | $-20.5M | $-55.00 | — |
| Q2 2023 | $0.00 | NaN% | $-13.6M | $-13.6M | $-46.65 | — |
| Q4 2022 | $0.00 | NaN% | $-25.4M | $-11.8M | $-44.40 | — |
| FY 2022 | $10.0K | 100.0% | $-25.4M | $-25.0M | $-95.00 | — |